Navigation Links
CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research
Date:8/4/2009

EINDHOVEN, The Netherlands, August 4 /PRNewswire/ -- With today's final approval of a research project into prostate cancer, the Dutch CTMM (Center for Translational Molecular Medicine) today announced the successful completion of 265 million euro funding for translational (bench-to-bedside) medical research, making CTMM one of the largest public-private partnerships in the world. This pivotal point in the organisation's development firmly positions the Netherlands as one of the world's leading destinations for translational biomedical research.

"The 15 million euro allocated to this prostate cancer project, which brings the total allocated CTMM funding to 265 million euro, should enable the project team to make a real difference to the diagnosis and treatment of a disease that counts among the biggest killers of men," said Peter Luijten, CTMM Chief Scientific Officer.

With this final project approval, CTMM has fulfilled the initial objectives of its business plan by establishing public-private research consortia to address the world's most prevalent diseases. The CTMM project portfolio now comprises 18 projects conducting translational molecular medicine research into innovative new techniques for the diagnosis and treatment of cancer, cardiovascular, neurodegenerative and infectious/auto-immune disease. In total, more than 100 partners from industry and academia are involved in the projects, which are funded on the basis of 25% from industry, 25% from academia and 50% from the Dutch government.

About CTMM

CTMM (Center for Translational Molecular Medicine) is a Netherlands-based public-private partnership dedicated to the development of technologies in molecular medicine that enable early diagnosis and personalised treatment for oncology, cardiovascular, neurodegenerative and infectious/auto-immune disease - the four main areas of disease causing mortality and diminished quality of life in the western world. CTMM operates by inviting, assessing and funding multidisciplinary projects that involve active participation by Netherlands-based academia and industry. All CTMM projects are judged by an independent International Scientific Advisory Committee and approved by a Supervisory Board based on their significant potential to translate research knowledge into clinical practice. CTMM is funded by the Dutch government (50%), academia (25%) and industry (25%). For more information, visit http://www.ctmm.nl

For specific information on the projects visit http://www.ctmm.nl


'/>"/>
SOURCE CTMM
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
2. Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy
3. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. PSA Screening Cuts Deaths by 20%, Says Worlds Largest Prostate Cancer Study
6. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
7. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
8. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
9. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
10. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
11. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
Breaking Medicine News(10 mins):